EdiGene Inc., a Beijing, China-based genome editing biotech company, raised approximately $15M in a Series pre-B financing.
The round was led by new investor Lilly Asia Ventures (LAV) with participation from new investor Huagai Capital and existing investors IDG Capital, WI Harper Group and others.
The company intends to use the funds to continue advancing its portfolio of therapeutic programs based on gene-editing technologies.
Led by Dr. Dong Wei, CEO, and Dr. Wensheng Wei, founder, EdiGene aims to translate genome editing technologies into novel therapeutics for genetic diseases and cancer, and to conduct high-throughput genome screening to enable dissection of functional big data in biological contexts.
The company has operational subsidiaries in Guangzhou, China and Cambridge, USA.